Abstract:
BACKGROUND:CAMPATH-1 Abs have been used for T-cell depletion in stem-cell transplantation since the early 1980s. During that time there has been substantial progress in manufacturing techniques and quality control procedures. This article summarizes the methods used to produce the Abs for clinical use and describes results of quality control tests on representative batches. METHODS:Rat hybridoma and recombinant CHO cells were cultured in hollow-fiber fermentors. Antibodies were purified from the culture supernatant by fractionation with ammonium sulphate, or by column chromatography. Additional steps were added to assure the removal of DNA and viruses. A range of analytical methods was used to characterize the antibodies. Samples were stored frozen at -70 degrees C and re-analyzed many years later to assess the long-term stability. RESULTS:Hollow-fiber fermentors provided a simple and reliable means for antibody production, with yields between 3-10 mg/h and a convenient concentration for further processing (0.6-2.0 mg/mL). All of the CAMPATH-1 Abs (rat IgM, rat IgG2b and human IgG1) could be purified by affinity chromatography on Protein A, but the low pH required for elution caused unacceptable aggregation of the IgM. CAMPATH-1H contained approx. 20% dimeric IgG, which could be removed by size exclusion chromatography. Antibodies were stable for at least 6 years at -70 degrees C, but there was unacceptable aggregation of CAMPATH-1M in one batch stored for 9 years. DISCUSSION:Pilot-scale production of MAbs for clinical studies is feasible in a small academic center, but regulatory requirements now demand that great attention is paid to all aspects of manufacturing and quality assurance. Although the underlying principles of cell culture and protein chemistry remain the same, the level of documentation, validation and quality control has increased greatly over the last 20 years.
journal_name
Cytotherapyjournal_title
Cytotherapyauthors
Phillips J,Drumm A,Harrison P,Bird P,Bhamra K,Berrie E,Hale Gdoi
10.1080/146532401753174061keywords:
subject
Has Abstractpub_date
2001-01-01 00:00:00pages
233-42issue
3eissn
1465-3249issn
1477-2566pii
S1465-3249(01)70984-Xjournal_volume
3pub_type
杂志文章相关文献
CYTOTHERAPY文献大全abstract:BACKGROUND AIMS:Clinical results from acute myocardial infarction (AMI) patients treated with MultiStem®, a large-scale expanded adherent multipotent progenitor cell population (MAPC), have demonstrated a strong safety and benefit profile for these cells. The mechanism of benefit with MAPC treatment is a result, in par...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.3109/14653249.2012.688945
更新日期:2012-09-01 00:00:00
abstract:BACKGROUND AIMS:Mesenchymal stromal cells (MSC) have been shown to be a promising candidate for tissue regeneration and cancer therapy. However, their therapeutic potential against chemotherapy-induced side-effects remains unclear. METHODS:We treated murine Lewis lung carcinoma (LLC) and xenograft human colon tumors w...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.3109/14653249.2011.646044
更新日期:2012-04-01 00:00:00
abstract:BACKGROUND AIMS:Allogeneic hematopoietic stem cell transplantation is curative for sickle cell disease, and the use of matched related donors, non-myeloablative conditioning and sirolimus immunosuppression results in stable mixed chimerism without graft-versus-host disease (GVHD). However, the time to terminate sirolim...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2019.10.003
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:Although a preponderance of pre-clinical data demonstrates the immunosuppressive potential of mesenchymal stromal cells (MSCs), significant heterogeneity and lack of critical quality attributes (CQAs) based on immunosuppressive capacity likely have contributed to inconsistent clinical outcomes. This heteroge...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2018.10.008
更新日期:2019-01-01 00:00:00
abstract:BACKGROUND AIMS:We have confirmed that aortic aneurysm (AA) can be regressed by the administration of bone marrow-derived mesenchymal stromal cells (BM-MSCs). We investigated the kinetics of signaling pathways in AA following treatment with BM-MSCs. METHODS:Angiotensin II-infused apolipoprotein E-deficient mice were t...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2017.07.010
更新日期:2017-10-01 00:00:00
abstract:BACKGROUND AIMS:Umbilical cord blood (UCB) provides an alternative source for hematopoietic stem/progenitor cells (HSPCs) in the treatment of hematological malignancies. However, clinical usage is limited due to the low quantity of HSPCs in each unit of cord blood and defects in bone marrow homing. Hyperbaric oxygen (H...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2017.08.020
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND AIMS:Treatment of tendon-derived stem cells (TDSCs) with connective tissue growth factor (CTGF) and ascorbic acid promoted their tenogenic differentiation. We investigated the effects of TDSCs pre-treated with CTGF and ascorbic acid on tendon repair in a patellar tendon window injury rat model. METHODS:Gree...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2015.10.005
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND AIMS:The purpose of this study was to investigate the neuroprotective effects of bone marrow bone marrow-derived and adipose tissue-derived mesenchymal stromal cells (MSCs) that were intravitreally transplanted in an experimental ocular hypertension (OHT) model. METHODS:An OHT rat model was generated by mea...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2014.12.005
更新日期:2015-05-01 00:00:00
abstract:BACKGROUND AIMS:The purpose of this study was to observe the clinical effect and safety of umbilical cord mesenchymal stem cells (UC-MSCs) in treating spinal cord injury (SCI) by intrathecal injection. METHODS:From January 2008 to October 2010, we treated 22 patients with SCI with UC-MSCs by intrathecal injection; dos...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2012.09.005
更新日期:2013-02-01 00:00:00
abstract:BACKGROUND:Adipose-derived stromal cells (ASCs) are a promising new therapeutic option for patients with acute myocardial infarction (AMI). Previously, we found that ASCs coupled to antibody-targeted microbubbles (StemBells [StBs]) improved cardiac function when administered intravenously 7 days post-AMI in rats. In th...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2016.10.004
更新日期:2017-01-01 00:00:00
abstract:BACKGROUND AIMS:Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic approaches. However, a characterization of the population of adipose-derived stromal and stem cells (ASCs) with the greatest therapeutic potential remains unclear. Under the authority of International Fede...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2013.02.006
更新日期:2013-06-01 00:00:00
abstract:BACKGROUND AIMS:Corticosteroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but they are associated with many complications, and less than half of patients have a sustained response. METHODS:To improve outcomes, we performed a retrospective study to analyze the efficacy of the ad...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2020.03.003
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:Traditionally, following high-dose therapy (HDT), unmanipulated autologous PBPC are infused. Alternatively, purified CD34+ cells can now be obtained by immunomagnetic separation using the CliniMACS device. Limited data currently exist examining hemopoietic recovery with such cells. METHODS:Ten patients with...
journal_title:Cytotherapy
pub_type: 临床试验,杂志文章
doi:10.1080/146532402317381857
更新日期:2002-01-01 00:00:00
abstract::Mesenchymal stem cells (MSC) are multipotent cells that differentiate into osteoblasts, myocytes, chondrocytes and adipocytes as well as insulin-producing cells. The mechanism underlying their in vivo differentiation is not clear and is thought to be caused by spontaneous cell fusion or factors present in the microenv...
journal_title:Cytotherapy
pub_type: 杂志文章,评审
doi:10.1080/14653240903080367
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Dendritic cells (DCs) that are derived from hematopoietic stem cells (HSCs) are the most potent antigen-presenting cells and play a pivotal role in initiating the immune response. Hence, large-scale production and direct induction of functional DCs ex vivo from HSCs are crucial to HSC research and clinical p...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2019.04.059
更新日期:2019-07-01 00:00:00
abstract:BACKGROUND:The use of myeloma Ag-loaded mature DC vaccines, cryopreserved in single-use aliquots, is an attractive immunotherapeutic strategy. In this study we investigated the retention of phenotype, viability and potency of DC vaccines after freezing and thawing. METHODS:Plastic-adherent monocytes, derived from a st...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1080/14653240510027235
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:Mismatched family donor and unrelated donor BM transplants are associated with a high risk of acute GvHD. White T-cell depletion is the best method to reduce risk of acute GvHD, there was a reluctance to use T-cell depletion in the mismatched setting because of increased risk of rejection and relapse. Partia...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1080/0032472031000141284
更新日期:1999-01-01 00:00:00
abstract:BACKGROUND AIMS:Cartilage tissue engineering with human mesenchymal stromal cells (hMSC) is promising for allogeneic cell therapy. To achieve large-scale hMSC propagation, scalable microcarrier-based cultures are preferred over conventional static cultures on tissue culture plastic. Yet it remains unclear how microcarr...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2016.03.293
更新日期:2016-06-01 00:00:00
abstract:BACKGROUND AIMS:Traditionally, stem cell therapy for myocardial infarction (MI) has been administered as a single treatment in the acute or subacute period after MI. These time intervals coincide with marked differences in the post-infarct myocardial environment, raising the prospect that repeat cell dosing could provi...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2013.07.016
更新日期:2014-04-01 00:00:00
abstract:BACKGROUND:Transplantation of mesenchymal stem cells (MSC) in rodent models has proved to be an effective therapeutic approach for spinal cord injury (SCI). However, further studies in primate models are still needed before clinical application of MSC to patients. METHODS:MSC were isolated from rhesus monkey BM and in...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1080/14653240600760808
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:Adipose tissue contains a stromal vascular fraction that can be easily isolated and provides a rich source of adipose tissue-derived mesenchymal stem cells (ASC). These ASC are a potential source of cells for tissue engineering. We studied whether the yield and growth characteristics of ASC were affected by ...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1080/14653240600621125
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND AIMS:It is important to improve the migratory ability of dendritic cells (DCs) and to increase DC potency for successful DC-based cancer immunotherapy. The intracellular Ca(2+) signaling pathway has an important role on the regulation of DC migration. Our preliminary studies revealed that sarco/endoplasmic r...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2015.06.002
更新日期:2015-10-01 00:00:00
abstract:BACKGROUND AIMS:The aim was to investigate the therapeutic effect of granulocyte-colony-stimulating factor (G-CSF) administration following implantation of autologous bone marrow mononuclear cells (BM MNC) for patients with lower limb ischemia. METHODS:The design was a randomized controlled trial. Fifteen patients wit...
journal_title:Cytotherapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3109/14653240903518163
更新日期:2010-10-01 00:00:00
abstract:BACKGROUND AIMS:Stem cells derived from human adipose tissue (ASC) have the capacity for renewal, are easily obtained and have plasticity properties that allow them to differentiate into several cell types, including osteoblast cells. With the aim of understanding the issue of the osteogenic process and finding reliabl...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.3109/14653240903580270
更新日期:2010-07-01 00:00:00
abstract::More precise quantitation of cellular immune responses has become possible with the advent of single-cell assays of immune function, such as cytokine flow cytometry, enzyme-linked immunospot (ELISPOT), and MHC-peptide multimers. Cytokine flow cytometry is an attractive technique because it allows the detection of resp...
journal_title:Cytotherapy
pub_type: 杂志文章,评审
doi:10.1080/14653240310000029
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND AIMS:Adoptive immunotherapy with the use of chimeric antigen receptor (CAR)-engineered T cells specific for CD19 has shown promising results for the treatment of B-cell lymphomas and leukemia. This therapy involves the transduction of autologous T cells with a viral vector and the subsequent cell expansion. ...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2013.06.003
更新日期:2013-11-01 00:00:00
abstract:BACKGROUND AIMS:Mesenchymal stromal cells (MSCs) suppress T-cell proliferation, especially after activation with inflammatory cytokines. We compared the dynamic action of unprimed and interferon (IFN)-γ plus tumor necrosis factor (TNF)-α-pretreated human bone marrow-derived MSCs on resting or activated T cells. METHOD...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2013.11.008
更新日期:2014-02-01 00:00:00
abstract:BACKGROUND AIMS:Bone marrow-derived mesenchymal stromal cells (MSCs) have been reported to suppress T-cell proliferation and used to alleviate the symptoms of graft-versus-host disease (GVHD). MSCs are a mixed cell population and at this time there are no tools to isolate the cells responsible for the T-cell suppressio...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1016/j.jcyt.2018.10.002
更新日期:2018-12-01 00:00:00
abstract:BACKGROUND:Cell therapy has been proposed as a salvage limb procedure in critical limb ischemia (CLI). In spite of the fact that clinical trials found some efficacy, the mechanism of action remains elusive. The objective of this study was to characterize two autologous cell therapy products (CTPs) obtained from patient...
journal_title:Cytotherapy
pub_type: 临床试验,杂志文章
doi:10.1016/j.jcyt.2016.10.013
更新日期:2017-02-01 00:00:00
abstract:BACKGROUND:Tumor cell lines have enormous value for the study of different aspects of cancer biology and have also recently gained great importance in autologous cell-based anti-tumor therapies. However, the use of these cells is still limited because in vitro growth is hampered by suboptimal culture conditions and cur...
journal_title:Cytotherapy
pub_type: 杂志文章
doi:10.1080/14653240701385836
更新日期:2007-01-01 00:00:00